Evidence map›Paper›PMID 34868397›Full record

ArticleDisease markers2021

Upregulated Transcription Factor PITX1 Predicts Poor Prognosis in Kidney Renal Clear Cell Carcinoma-Based Bioinformatic Analysis and Experimental Verification.

Yinglang Zhang, Zhe Zhang, Wei Zhang, Hailong Hu, Guochang Bao

Open access · hybridAbstract read
In one paragraph

Article in Disease markers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. PITX1 plays essential functions in cancer.Frontiers in oncology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Yinglang Zhang *Department of Urology, Affiliated Hospital of Chifeng University, 024000 Chifeng, Inner Mongolia, China.ORCID https://orcid.org/0000-0003-0205-2878
Zhe Zhang *Department of Urology, The Second Hospital of Tianjin Medical University, 300211 Tianjin, China.ORCID https://orcid.org/0000-0002-3938-4190
Wei ZhangDepartment of Urology, Affiliated Hospital of Chifeng University, 024000 Chifeng, Inner Mongolia, China.
Hailong HuDepartment of Urology, The Second Hospital of Tianjin Medical University, 300211 Tianjin, China.ORCID https://orcid.org/0000-0002-8952-4147
Guochang BaoDepartment of Urology, Affiliated Hospital of Chifeng University, 024000 Chifeng, Inner Mongolia, China.ORCID https://orcid.org/0000-0001-9982-1391
Chifeng University · CNSecond Hospital of Tianjin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Paired-like homeodomain transcription factor 1 (PITX1) is involved in numerous biological processes, including cell growth, progression, and invasion in various malignant tumors. Nevertheless, the relationship between PITX1 and kidney renal clear cell carcinoma (KIRC) remains unclear. The clinical role and functions of PITX1 were analyzed by integrating multiple open-access online datasets. Further experimental verification was performed via quantitative real-time PCR (qRT-PCR) to detect the expression of PITX1 in 10 pairs of KIRC tissues. Our results revealed that PITX1 mRNA was overexpressed in tumor tissues compared with normal tissues in the TCGA-KIRC database (

Indexed as

Up-RegulationCarcinoma, Renal CellCohort StudiesComputational BiologyFemaleHumansKidney NeoplasmsMaleMiddle AgedPaired Box Transcription FactorsPrognosisProportional Hazards ModelsRNA, MessengerSurvival Analysishomeobox protein PITX1Paired Box Transcription FactorsRNA, Messenger

Identifiers

PMID34868397
PMCPMC8633854
OpenAlexW3214916987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.